ArticleFrontiers in oncology2025
Clinical features and mutational frequency of renal cell carcinoma from patients undergoing kidney transplant evaluation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Patients with chronic kidney disease (CKD) or post-kidney transplant have an elevated risk of renal cell carcinoma (RCC). Despite increased understanding of genomic alterations in clear cell and papillary RCC, the most common subtypes, little is known about the effects of renal dysfunction on RCC pathogenesis. Materials and methods: This retrospective study analyzed electronic medical records and pathology data from adult patients with renal cell carcinoma (RCC) who were evaluated for or received a kidney transplant at a single institution between 1995 and 2021. Molecular sequencing of RCC tissue samples was conducted to compare mutation rates in patients with renal dysfunction compared with those reported by The Cancer Genome Atlas (TCGA). Results: This study identified 21 patients with RCC undergoing kidney transplant evaluation, mostly males with an increased occurrence of papillary RCC (38.1%) and early-stage disease (85.7%). Among clear cell RCC tumors, Conclusions: This study identifies key mutations in RCC among patients with CKD and post-kidney transplant, highlighting a complex relationship between renal dysfunction, inflammation, and tumorigenesis. Despite its limited sample size, the findings underscore the need for further research to understand the molecular drivers of RCC in high-risk populations, which could lead to more personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.